Barclays lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $190 from $200 and keeps an Overweight rating on the shares. The company’s Q3 revenue beat was driven by strong growth across key growth drivers Xywav and Epidiolex, while Rylaze was temporarily impacted by update in treatment protocol, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ: